Mr. Allinson is Senior Director for Research, serving as the principal administrator for Cancer, Surgical Advancement and Interventional Endoscopy research units. Mr. Allinson oversees research operations and partnerships for NCI strategy, clinical trials, translational research, cancer-oriented population health and value-based care research, surgical and precision medicine. He focuses on strategic planning for NCI and CCSG compliance. He coordinates closely with physician leadership and medical directorship, and leads a dynamic team of research unit leaders with specific experience in their field. He currently serves on the Central Florida chapter for BIOFlorida, a state-wide biotechnology trade association.
Mr. Allinson has a long-standing history of service with integrated health institutions, academic medical centers and NCI designated institutions. He previously led state-wide clinical trials and venture initiatives in New York for the SUNY System, in Texas for the University of Texas System and in Pennsylvania for Geisinger Health. He facilitated key initiatives in service of UT MD Anderson, UT Southwestern and UT Health institutions in San Antonio, Houtson and Tyler. He is the retired principal investigator (PI) for the New York State Innovation Model (SIM) funded by CMS with a focus on value-based care and population health. With support of the UT Board of Regents, Allinson founded the UT Horizon Fund, a $60 million initiative. He spun-out Lung Therapeutics out of UT, recognized by JP Morgan Healthcare in 2016 as “One of Five Companies to Watch”, and served on the board. He led intellectual property royalty monetization for the Pfizer drug SOMAVERT®, valued $52+ million. He served as the primary architect for precision medicine and genomics programs at Geisinger. He served as PI on research grants associated with the NIH, DoD and philanthropic and foundational grants.